Investing.com - Cellectis reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Cellectis announced earnings per share of $-0.33 on revenue of $13.9M. Analysts polled by Investing.com anticipated EPS of $-0.7811 on revenue of $7.25M.
Cellectis shares are down 28.64% from the beginning of the year, still down 44.37% from its 52 week high of $34.71 set on January 20. They are under-performing the Nasdaq which is down 1.28% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by AbbVie on February 3, who reported EPS of $2.92 on revenue of $13.86B, compared to forecasts EPS of $2.85 on revenue of $13.7B.
Merck&Co had missed expectations on February 4 with fourth quarter EPS of $1.32 on revenue of $12.51B, compared to forecast for EPS of $1.38 on revenue of $12.67B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar